ACT & A2AR antagonism  ➣ T cells:
anti-HER2 CAR+ (135)
OT-I (OVA-specific) (388, 396)
TDLN-derived (402)
Reactive to CMS4 (38)
➣ A2AR antagonists:
CPI-444 (396)
ZM241385 (38, 135, 402)
KW6002 (402)
SCH58261 (135, 388)  ➣ Breast: E0771- HER2 (135)
➣ Melanoma: B16-OVA (396)
➣ Ovarian: ID8-OVA (388)
➣ Fibrosarcoma:
MCA205 (402)
24JK-HER2 (135)
➣ Sarcoma CMS4 (38)  ➣ Primary tumor expansion rate ↓ (135, 396)
PD-1 ICB (135)
IFN-γ (135)
➣ Metastasis formation ↓ (38, 402)
Non-myeloablative pretreatment (402)
➣ Survival ↑ (135, 388, 396, 402) PD-1 ICB (135)  ↑ Adoptively transferred T cells (396)↑ Tbet, 41BB, CD69 in/on adoptively transferred CD8+ cells (396)↑ IFN-γ+ adoptively transferred T cells (135)↑ Stimulation-induced IFN-γ, TNF-α production by adoptively transferred CD8+ T cells (396)↑ Stimulation-induced IFN-γ production by adoptively transferred CD8+ or CD4+ T cells (402)↑ Tbet, 41BB in/on endogenous CD44+ CD8+ cells (396)↑ Stimulation-induced IL-2, IFN-γ, TNF-α production by endogenous CD8+CD44+ T cells (396)